Drug CEO Targeted by Clinton Is Criticized by Drug LobbyBy
Turing "does not represent" values of drugmakers, group says
Drugmaker acquired old medicine, raised price 50-fold
The top U.S. pharmaceutical lobby group said a drug company that has drawn criticism for a 50-fold price increase of a decades-old drug doesn’t match its companies’ values.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.